Bases de données pharmaceutiques : Questions médicales fréquentes
Nom anglais: Databases, Pharmaceutical
Descriptor UI:D062313
Tree Number:L01.470.750.750.400
Termes MeSH sélectionnés :
Platelet Function Tests
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bases de données pharmaceutiques : Questions médicales les plus fréquentes",
"headline": "Bases de données pharmaceutiques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bases de données pharmaceutiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bases de données pharmaceutiques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Bases de données factuelles",
"url": "https://questionsmedicales.fr/mesh/D016208",
"about": {
"@type": "MedicalCondition",
"name": "Bases de données factuelles",
"code": {
"@type": "MedicalCode",
"code": "D016208",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "L01.470.750.750"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Bases de données pharmaceutiques",
"alternateName": "Databases, Pharmaceutical",
"code": {
"@type": "MedicalCode",
"code": "D062313",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Michele B Kaufman",
"url": "https://questionsmedicales.fr/author/Michele%20B%20Kaufman",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Konstantinos Vezertzis",
"url": "https://questionsmedicales.fr/author/Konstantinos%20Vezertzis",
"affiliation": {
"@type": "Organization",
"name": "School of Electrical and Computer Engineering, Biomedical Engineering Laboratory, National Technical University of Athens, Heroon Polytecniou 9, Athens, 15780, Athens, Greece."
}
},
{
"@type": "Person",
"name": "George I Lambrou",
"url": "https://questionsmedicales.fr/author/George%20I%20Lambrou",
"affiliation": {
"@type": "Organization",
"name": "School of Electrical and Computer Engineering, Biomedical Engineering Laboratory, National Technical University of Athens, Heroon Polytecniou 9, Athens, 15780, Athens, Greece."
}
},
{
"@type": "Person",
"name": "Dimitrios Koutsouris",
"url": "https://questionsmedicales.fr/author/Dimitrios%20Koutsouris",
"affiliation": {
"@type": "Organization",
"name": "School of Electrical and Computer Engineering, Biomedical Engineering Laboratory, National Technical University of Athens, Heroon Polytecniou 9, Athens, 15780, Athens, Greece."
}
},
{
"@type": "Person",
"name": "Piotr Ozieranski",
"url": "https://questionsmedicales.fr/author/Piotr%20Ozieranski",
"affiliation": {
"@type": "Organization",
"name": "Department of Social and Policy Sciences, University of Bath, Bath, United Kingdom."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Validation of immunofluorescence analysis of blood smears in patients with inherited platelet disorders.",
"datePublished": "2023-01-10",
"url": "https://questionsmedicales.fr/article/36732160",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtha.2022.12.031"
}
},
{
"@type": "ScholarlyArticle",
"name": "The rate of platelet activation determines thrombus size and structure at arterial shear.",
"datePublished": "2023-04-19",
"url": "https://questionsmedicales.fr/article/37085037",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtha.2023.03.044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Platelet inhibition by low-dose aspirin is not influenced by body mass or weight.",
"datePublished": "2022-06-29",
"url": "https://questionsmedicales.fr/article/35768902",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/09537104.2022.2087868"
}
},
{
"@type": "ScholarlyArticle",
"name": "Platelet dysfunction persists after trauma despite balanced blood product resuscitation.",
"datePublished": "2022-10-22",
"url": "https://questionsmedicales.fr/article/36280503",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.surg.2022.09.017"
}
},
{
"@type": "ScholarlyArticle",
"name": "Time from blood draw to multiple electrode aggregometry and association with platelet reactivity.",
"datePublished": "2022-11-08",
"url": "https://questionsmedicales.fr/article/36344849",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11239-022-02720-7"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Sciences de l'information",
"item": "https://questionsmedicales.fr/mesh/D007254"
},
{
"@type": "ListItem",
"position": 3,
"name": "Mémorisation et recherche des informations",
"item": "https://questionsmedicales.fr/mesh/D016247"
},
{
"@type": "ListItem",
"position": 4,
"name": "Bases de données comme sujet",
"item": "https://questionsmedicales.fr/mesh/D019992"
},
{
"@type": "ListItem",
"position": 5,
"name": "Bases de données factuelles",
"item": "https://questionsmedicales.fr/mesh/D016208"
},
{
"@type": "ListItem",
"position": 6,
"name": "Bases de données pharmaceutiques",
"item": "https://questionsmedicales.fr/mesh/D062313"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bases de données pharmaceutiques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bases de données pharmaceutiques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bases de données pharmaceutiques",
"description": "Comment identifier un médicament dans une base de données ?\nQuelles informations sont disponibles sur les effets secondaires ?\nComment vérifier les interactions médicamenteuses ?\nPeut-on trouver des informations sur les médicaments génériques ?\nComment évaluer l'efficacité d'un médicament ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Platelet+Function+Tests&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bases de données pharmaceutiques",
"description": "Où trouver des informations sur les symptômes liés à un médicament ?\nComment les symptômes sont-ils classés dans les bases ?\nLes bases fournissent-elles des exemples de symptômes ?\nComment les symptômes sont-ils liés aux médicaments ?\nPeut-on trouver des symptômes rares dans les bases ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Platelet+Function+Tests&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bases de données pharmaceutiques",
"description": "Les bases fournissent-elles des conseils de prévention ?\nComment prévenir les interactions médicamenteuses ?\nY a-t-il des recommandations pour les populations à risque ?\nComment les bases aident-elles à la prévention des maladies ?\nPeut-on trouver des stratégies de prévention dans les bases ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Platelet+Function+Tests&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bases de données pharmaceutiques",
"description": "Comment rechercher des traitements dans une base de données ?\nLes bases incluent-elles des protocoles de traitement ?\nComment comparer l'efficacité de différents traitements ?\nPeut-on trouver des alternatives aux traitements ?\nComment les traitements sont-ils mis à jour dans les bases ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Platelet+Function+Tests&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bases de données pharmaceutiques",
"description": "Comment identifier les complications liées à un médicament ?\nLes bases fournissent-elles des études de cas sur les complications ?\nComment les complications sont-elles signalées dans les bases ?\nPeut-on trouver des statistiques sur les complications ?\nComment prévenir les complications médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Platelet+Function+Tests&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bases de données pharmaceutiques",
"description": "Quels facteurs de risque sont associés aux médicaments ?\nComment les bases évaluent-elles les facteurs de risque ?\nPeut-on trouver des recommandations sur les facteurs de risque ?\nComment les facteurs de risque influencent-ils le traitement ?\nLes bases incluent-elles des informations sur les facteurs de risque environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Platelet+Function+Tests&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un médicament dans une base de données ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez le nom commercial, le principe actif ou le code ATC pour rechercher."
}
},
{
"@type": "Question",
"name": "Quelles informations sont disponibles sur les effets secondaires ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases fournissent des listes d'effets indésirables et leur fréquence."
}
},
{
"@type": "Question",
"name": "Comment vérifier les interactions médicamenteuses ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez les sections dédiées aux interactions dans les bases de données."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des informations sur les médicaments génériques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases de données incluent des informations sur les équivalents génériques."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un médicament ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Recherchez des études cliniques et des revues systématiques dans les bases."
}
},
{
"@type": "Question",
"name": "Où trouver des informations sur les symptômes liés à un médicament ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases de données listent les symptômes associés aux effets secondaires."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils classés dans les bases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont souvent classés par système corporel ou par fréquence d'apparition."
}
},
{
"@type": "Question",
"name": "Les bases fournissent-elles des exemples de symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des exemples pour chaque médicament et ses effets."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils liés aux médicaments ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases établissent des liens entre médicaments et symptômes rapportés."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des symptômes rares dans les bases ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases documentent également des effets indésirables rares."
}
},
{
"@type": "Question",
"name": "Les bases fournissent-elles des conseils de prévention ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des recommandations pour éviter les effets indésirables."
}
},
{
"@type": "Question",
"name": "Comment prévenir les interactions médicamenteuses ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez les bases pour identifier les médicaments à éviter ensemble."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les populations à risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases fournissent des conseils spécifiques pour les groupes vulnérables."
}
},
{
"@type": "Question",
"name": "Comment les bases aident-elles à la prévention des maladies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles offrent des informations sur les médicaments préventifs et leur utilisation."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des stratégies de prévention dans les bases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des stratégies basées sur des données probantes pour la prévention."
}
},
{
"@type": "Question",
"name": "Comment rechercher des traitements dans une base de données ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez des mots-clés comme le nom du médicament ou la pathologie traitée."
}
},
{
"@type": "Question",
"name": "Les bases incluent-elles des protocoles de traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles fournissent des recommandations et des protocoles basés sur des preuves."
}
},
{
"@type": "Question",
"name": "Comment comparer l'efficacité de différents traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez les études comparatives et les méta-analyses disponibles."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des alternatives aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases proposent souvent des alternatives thérapeutiques."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils mis à jour dans les bases ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases sont régulièrement mises à jour avec les dernières recherches et recommandations."
}
},
{
"@type": "Question",
"name": "Comment identifier les complications liées à un médicament ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases de données listent les complications possibles et leur fréquence."
}
},
{
"@type": "Question",
"name": "Les bases fournissent-elles des études de cas sur les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des études de cas documentant des complications spécifiques."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles signalées dans les bases ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont souvent signalées par des professionnels de santé et des patients."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des statistiques sur les complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases fournissent des données statistiques sur la fréquence des complications."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications médicamenteuses ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases offrent des recommandations pour minimiser les risques de complications."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux médicaments ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases identifient des facteurs comme l'âge, le sexe et les comorbidités."
}
},
{
"@type": "Question",
"name": "Comment les bases évaluent-elles les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles utilisent des études épidémiologiques et des données cliniques pour évaluer."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des recommandations sur les facteurs de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases fournissent des recommandations pour gérer les facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque influencent-ils le traitement ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent modifier le choix du médicament et la posologie recommandée."
}
},
{
"@type": "Question",
"name": "Les bases incluent-elles des informations sur les facteurs de risque environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent inclure des facteurs environnementaux influençant l'efficacité."
}
}
]
}
]
}
Inherited platelet disorders (IPDs) are rare diseases characterized by reduced blood platelet counts and/or impaired platelet function. Recognizing IPDs is advisable but often challenging. The diagnos...
The aim of the present study was to validate immunofluorescence microscopy as a screening tool for IPDs in comparison with genetic screening....
We performed a blinded comparison between the diagnosis made using immunofluorescence microscopy on blood smears and genetic findings in a cohort of 43 families affected with 20 different genetically ...
Immunofluorescence correctly predicted the underlying IPD in the vast majority of patients with 1 of 9 IPDs for which the typical morphologic pattern is known. Thirty of the 43 enrolled families (70%)...
Immunofluorescence microscopy on blood smears is an effective screening tool for 9 forms of IPD, which include the most frequent forms of inherited thrombocytopenia. Using this approach, typical chang...
The response of platelets to activating stimuli and pharmaceutical agents varies greatly within the normal population. Current platelet function tests are used to measure end-point levels of platelet ...
To identify variability, to agonists and among individuals, in platelet activation kinetics and assess the impact of this on thrombus formation....
We have developed a bespoke real-time flow cytometry assay and analysis package to measure the rate of platelet activation over time using 2 parameters of platelet activation, fibrinogen binding and P...
The rate of platelet activation varied considerably within the normal population but did not correlate with maximal platelet activation, demonstrating that platelet activation rate is a separate and n...
For the first time, we have shown that platelet response rate corresponds to thrombus size and structure, wherein faster responders form larger, more densely packed thrombi at arterial, but crucially ...
Aspirin's clinical efficacy may be influenced by body weight and mass. Although inadequate platelet inhibition by aspirin is suggested as responsible, evidence for this in non-diabetic patients is spa...
Platelet activation and aggregation are critical to the initiation of hemostasis after trauma with hemorrhage. Platelet dysfunction is a well-recognized phenomenon contributing to trauma-induced coagu...
A retrospective secondary cohort study of platelet count and function was performed using samples from the Pragmatic Randomized Optimal Platelet and Plasma Ratios trial. Platelet characteristics were ...
In total, 680 patients were included for analysis. Platelet counts were significantly lower from baseline to 72 hours after hospital admission with further 1.3 to 2-fold reductions noted in nonsurvivo...
Platelet aggregability recovers 12 hours after injury independent of worsening thrombocytopenia. Failure of platelet function to recover portends a poor prognosis....
Results from multiple electrode aggregometry (MEA) may vary according to pre-analytic factors. This study aimed to analyze the association of time from blood draw to MEA in patients undergoing percuta...
Evidence surrounding P2Y12 platelet reactivity units (PRU) impact on bleeding outcomes in patients undergoing coronary artery bypass is varied. This study sought to assess whether on-pump CABG procedu...
This retrospective cohort study compared those with a PRU level ≤237 (low PRU group) to >237 (high PRU group). The primary outcome assessed massive or severe bleeding in accordance with universal defi...
A total of 69 patients were included, 47 in the low and 22 in the high PRU groups. Patients were a median (IQR) 66 (62-74) years and 84.1% (N.=58) were male. Most patients received clopidogrel prior t...
This study determined that low preoperative P2Y12 PRU levels may influence moderate bleeding in patients undergoing cardiac surgery, but not massive or severe bleeding....
Despite Antiplatelet therapy (APT), cardiovascular patients undergoing revascularisation remain at high risk for thrombotic events. Individual response to APT varies substantially, resulting in insuff...
To investigate residual platelet reactivity variability over time in individual patients undergoing carotid endarterectomy (CEA) treated with clopidogrel....
Platelet reactivity was determined in patients undergoing CEA in a prospective, single-centre, observational study using the VerifyNow (change in turbidity from ADP-induced binding to fibrinogen-coate...
Between December 2017 and November 2019, 50 patients undergoing CEA were included. Platelet reactivity measured with the VerifyNow (p = < .001) and VASP (p = .029) changed over time, while the PACT di...
In patients undergoing CEA, perioperative platelet reactivity measurements fluctuate over time with little agreement between platelet reactivity assays. Consequently, HTPR status of individual patient...
Heparin-induced thrombocytopenia (HIT), a severe autoimmune disorder, occurs in patients undergoing heparin therapy. The presence of platelet-activating antibodies against platelet factor 4/Heparin in...
High-on-treatment platelet reactivity (HTPR) has been established as a predictor of major adverse cardiovascular events (MACE) in patients undergoing percutaneous coronary interventions on dual antipl...
All consecutive patients treated with CAS in a single institution were enrolled in a prospective clinical study. HTPR was evaluated with 5 different laboratory assays carried out just before CAS. MACE...
A total of 300 patients were enrolled in the study, and eight were then excluded because blood samples resulted unsuitable for the laboratory testing or CAS aborted for technical problems. Median foll...
HTPR to three different assays (mainly to VASP + PFA P2Y+ VerifyNow) in patients on DAPT after CAS has predictive value for subsequent MACE. Prospective studies to assess whether platelet function tes...
Cigarette smoking is a potent modifiable risk factor for coronary artery disease (CAD). However, little is known about alterations to prothrombotic state and platelet reactivity early after smoking ce...
We investigated alterations to platelet reactivity, coagulation and markers of platelet, endothelial, inflammatory and coagulation activation in clopidogrel-treated patients with CAD after PCI before ...
Smoking patients aged 18 years or older at least 30 days after PCI were recruited and encouraged to quit the habit. At baseline and at 30 days, we measured platelet reactivity with VerifyNow system, t...
Among 117 patients, 84 patients (72%) at a median age of 60.5 years (40 [interquartile range 30-47] pack-years) completed a 30-day follow-up. At day 30, 30 (35.7%) patients stopped smoking with cotini...
After smoking cessation in CAD patients following PCI an increase in platelet reactivity and a decrease in P-selectin levels were observed. The risk of thrombotic complications post PCI might be parad...